JP2023156196A - 抗ＳＡＲＳ－ＣｏＶ－２抗体 - Google Patents

抗ＳＡＲＳ－ＣｏＶ－２抗体 Download PDF

Info

Publication number
JP2023156196A
JP2023156196A JP2022065933A JP2022065933A JP2023156196A JP 2023156196 A JP2023156196 A JP 2023156196A JP 2022065933 A JP2022065933 A JP 2022065933A JP 2022065933 A JP2022065933 A JP 2022065933A JP 2023156196 A JP2023156196 A JP 2023156196A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022065933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023156196A5 (https=
Inventor
佑太 松村
Yuta Matsumura
峻亮 稲浦
Shunsuke Inaura
大貴 西口
Hiroki Nishiguchi
重文 熊地
Shigefumi Kumachi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Epsilon Molecular Engineering Inc
Original Assignee
Kao Corp
Epsilon Molecular Engineering Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp, Epsilon Molecular Engineering Inc filed Critical Kao Corp
Priority to JP2022065933A priority Critical patent/JP2023156196A/ja
Priority to PCT/JP2023/014930 priority patent/WO2023199955A1/ja
Publication of JP2023156196A publication Critical patent/JP2023156196A/ja
Publication of JP2023156196A5 publication Critical patent/JP2023156196A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022065933A 2022-04-12 2022-04-12 抗ＳＡＲＳ－ＣｏＶ－２抗体 Pending JP2023156196A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022065933A JP2023156196A (ja) 2022-04-12 2022-04-12 抗ＳＡＲＳ－ＣｏＶ－２抗体
PCT/JP2023/014930 WO2023199955A1 (ja) 2022-04-12 2023-04-12 抗ＳＡＲＳ－ＣｏＶ－２抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022065933A JP2023156196A (ja) 2022-04-12 2022-04-12 抗ＳＡＲＳ－ＣｏＶ－２抗体

Publications (2)

Publication Number Publication Date
JP2023156196A true JP2023156196A (ja) 2023-10-24
JP2023156196A5 JP2023156196A5 (https=) 2025-04-02

Family

ID=88329816

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022065933A Pending JP2023156196A (ja) 2022-04-12 2022-04-12 抗ＳＡＲＳ－ＣｏＶ－２抗体

Country Status (2)

Country Link
JP (1) JP2023156196A (https=)
WO (1) WO2023199955A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111153991A (zh) * 2020-02-26 2020-05-15 北京博奥森生物技术有限公司 一种人SARS-CoV-2单克隆抗体及其制备方法和应用
CN112028993A (zh) * 2020-10-15 2020-12-04 武汉华美生物工程有限公司 一种抗sars-cov-2病毒n蛋白的纳米抗体及其制备方法和应用
WO2022181550A1 (ja) * 2021-02-25 2022-09-01 花王株式会社 抗ＳＡＲＳ－ＣｏＶ－２抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111153991A (zh) * 2020-02-26 2020-05-15 北京博奥森生物技术有限公司 一种人SARS-CoV-2单克隆抗体及其制备方法和应用
CN112028993A (zh) * 2020-10-15 2020-12-04 武汉华美生物工程有限公司 一种抗sars-cov-2病毒n蛋白的纳米抗体及其制备方法和应用
WO2022181550A1 (ja) * 2021-02-25 2022-09-01 花王株式会社 抗ＳＡＲＳ－ＣｏＶ－２抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRONT. IMMUNOL., vol. Vol.12, Article 719037, JPN6026006899, 26 July 2021 (2021-07-26), pages 1 - 9, ISSN: 0005801639 *
J. BIOL. CHEM., vol. 298, no. 1, JPN6026006900, January 2022 (2022-01-01), pages 101290 - 1, ISSN: 0005801638 *
PLOS PATHOGENS, vol. 17, no. 10, JPN6026006898, 2021, pages 1009542 - 1, ISSN: 0005801640 *

Also Published As

Publication number Publication date
WO2023199955A1 (ja) 2023-10-19

Similar Documents

Publication Publication Date Title
CN112010965B (zh) 一种针对新冠病毒SARS-CoV-2棘突蛋白RBD区的单克隆抗体及其应用
JP6215223B2 (ja) マルチプレックス免疫スクリーニングアッセイ
KR102671155B1 (ko) Ns1 단백질의 결합 단백질
KR102785081B1 (ko) 항 인간 심근 트로포닌 i의 항체 및 그 사용
KR102792597B1 (ko) Ns1-결합 단백질
US20210301000A1 (en) NS1-Binding Protein and Uses Thereof
CA3246923A1 (en) ANTIBODIES, MELTING PROTEIN AND RELATED USES
EP4299745A1 (en) Anti-sars-cov-2 antibody
KR102785236B1 (ko) 항 인간 심근 트로포닌 i의 항체 및 그 사용
JP7414225B2 (ja) ＳＡＲＳ－ＣｏＶ－２結合ペプチド
JP2023156196A (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体
JP7038367B2 (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体
JP2024151260A (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体
JP2023156197A (ja) ＳＡＲＳ－ＣｏＶ－２結合ペプチド
KR102709435B1 (ko) SARS-CoV-2 특이적 신규 항체를 이용한 SARS-CoV-2의 검출방법
JP7174961B2 (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体を用いた医薬品及び検査キット
CN121537507B (zh) 一种抗mers的纳米抗体、纳米抗体融合蛋白及其应用
CA3109433C (en) Ns1-binding protein and uses thereof
JP2024165150A (ja) ＳＡＲＳ－ＣｏＶ－２中和抗体
CN116547004A (zh) SARS-CoV-2结合肽
CN120349397A (zh) 乙型流感n蛋白特异性抗体及其制备方法与应用
CN120209137A (zh) 抗降钙素原纳米抗体及其应用
CN114805562A (zh) 抗新型冠状病毒人源化纳米抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224